Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background
: Well-differentiated papillary thyroid carcinoma (PTC) represents the thyroid neoplasia with the highest incidence. Long non-coding RNAs (lncRNAs) have been found deregulated in several human carcinomas, and hence, proposed as potential diagnostic and prognostic markers. Therefore, the aim of our study was to investigate their role in thyroid carcinogenesis.
Methods
: We analysed the lncRNA expression profile of 12 PTC and four normal thyroid tissues through a lncRNA microarray.
Results
: We identified 669 up- and 2470 down-regulated lncRNAs with a fold change >2. Among them, we focused on the down-regulated
RP5-1024C24.1
located in an antisense position with respect to the
MPPED2
gene which codes for a metallophosphoesterase with
tumour suppressor
activity. Both these genes are down-regulated in benign and malignant thyroid neoplasias. The restoration of
RP5-1024C24.1
expression in thyroid carcinoma cell lines reduced cell proliferation and migration by modulating the PTEN/Akt pathway. Inhibition of thyroid carcinoma cell growth and cell migration ability was also achieved by the
MPPED2
restoration. Interestingly,
RP5-1024C24.1
over-expression is able to increase
MPPED2
expression.
Conclusions
: Taken together, these results demonstrate that
RP5-1024C24.1
and
MPPED2
might be considered as novel
tumour suppressor
genes whose loss of expression contributes to thyroid carcinogenesis.
...
PMID:The Long Non-Coding RNA
RP5-1024C24.1
and Its Associated-Gene
MPPED2
Are Down-Regulated in Human Thyroid Neoplasias and Act as Tumour Suppressors. 2978 66